Although proteases control inflammation and pain, the identity, cellular origin, mechanism of action, and causative role of proteases that are activated during disease are not defined. We investigated the activation and function of cysteine cathepsins (Cat) in colitis. METHODS: Because protease activity, rather than expression, is regulated, we treated mice with fluorescent activity-based probes that covalently modify activated cathepsins. Activated proteases were localized by tomographic imaging of intact mice and confocal imaging of tissues, and were identified by electrophoresis and immunoprecipitation. We examined the effects of activated cathepsins on excitability of colonic nociceptors and on colonic pain, and determined their role in colonic inflammatory pain by gene deletion. RESULTS: Tomography and magnetic resonance imaging localized activated cathepsins to the inflamed colon of piroxicam-treated il10 Ϫ/Ϫ mice. Confocal imaging detected activated cathepsins in colonic macrophages and spinal neurons and microglial cells of mice with colitis. Gel electrophoresis and immunoprecipitation identified activated Cat-B, Cat-L, and Cat-S in colon and spinal cord, and Cat-S was preferentially secreted into the colonic lumen. Intraluminal Cat-S amplified visceromotor responses to colorectal distension and induced hyperexcitability of colonic nociceptors, which required expression of protease-activated receptor-2. Cat-S deletion attenuated colonic inflammatory pain induced with trinitrobenzene sulfonic acid. CONCLUSIONS: Activity-based probes enable noninvasive detection, cellular localization, and proteomic identification of proteases activated during colitis and are potential diagnostic tools for detection of predictive disease biomarkers. Macrophage cathepsins are activated during colitis, and Cat-S activates nociceptors to induce visceral pain via protease-activated receptor-2. Cat-S mediates colitis pain and is a potential therapeutic target.
P roteases in the gastrointestinal tract normally derive from digestive secretions and resident microbes. During inflammation, proteases from the circulation, immune and epithelial cells, and infective organisms become activated, and can induce disease by generating inflammatory agents and activating receptors and channels. However, the identity, cellular origin, and mechanism of action of proteases that are activated during inflammation are not fully established, and their causative roles in disease are uncertain.
Cysteine cathepsins (Cat) have diverse pathophysiological functions. 1, 2 Cathepsins are ubiquitous (eg, Cat-B, -L, -H, -C, -X, -F, -O) or exhibit cell-specific localization (Cat-S in immune cells). By degrading proteins in acidified lysosomes, endosomes, or exosomes, cathepsins control protein turnover (Cat-B, -L, -H), antigen presentation (Cat-V, -L, -S, -F), zymogen activation (Cat-B, -C), and hormone processing (Cat-B, -L). Certain cathepsins are also secreted, and can remain fully (Cat-S) or partially (Cat-B, Cat-L) active at normal extracellular pH, where activity is enhanced by the acidic inflammatory environment and is stabilized by glycosaminoglycans. Cathepsins have been implicated in cancer, osteoporosis, inflammatory/immune diseases, and allergic disorders. 1, 2 After nerve injury, Cat-S is up-regulated in spinal microglial cells, and secreted Cat-S liberates the neuronal chemokine fractalkine and thereby maintains neuropathic pain. 3, 4 Cat-S also cleaves protease-activated receptor-2 (PAR 2 ), 5 a receptor of nociceptive neurons that promotes neurogenic inflammation and pain in the skin and intestine. 6 -9 To determine the role of cathepsins in inflammatory diseases and pain, we investigated the activation, cellular origin, and function of cathepsins in colitis. Because proteases are regulated by zymogen processing and endogenous inhibitors that control activity rather than by regulation of gene or protein expression, we used activity-based probes (ABPs) to detect activated cathepsins. 10 ABPs constitute an inhibitorbased reactive warhead group that covalently binds with the active site with high specificity, a linker that prevents steric congestion, and a tag for detection. We used ABPs with an acyloxymethylketone warhead that binds to cysteine cathepsins, and a near-infrared reporter for optical imaging of cathepsin activities. 11, 12 We examined whether Cat-S, which was activated and secreted, excites colonic nociceptors and induces colonic pain, and determined the contribution of PAR 2 by gene deletion. By studying Cat-SϪdeficient mice, we defined the causative role of Cat-S in colonic inflammatory pain.
Methods
See Supplementary Materials for detailed methods.
Mice
C57BL/6 mice, il10 Ϫ/Ϫ mice, par 2 Ϫ/Ϫ and par 2 ϩ/ϩ mice, 13 and cat-s Ϫ/Ϫ and cat-s ϩ/ϩ mice 14 were studied. Institutional Animal Care Use Committees approved all procedures.
ABPs
ABPs with an acyloxymethylketone warhead included GB123, a nonquenched probe labeled with Cy5; GB138, a similar probe labeled with IR Dye 800; and GB137, a quenched probe with a dimethyl benzoic acid-based linker and a Cy5 fluorophore. 11, 12 Whereas GB123 and GB138 fluoresce whether or not they are bound to proteases, GB137 fluoresces only after proteolytic attack. These probes label Cat-B, Cat-L and Cat-S, and are serum-stable, cell-permeant, and are suitable for administration to animals and for optical imaging.
Induction of Colitis
Piroxicam-induced colitis in il10 ؊/؊ mice. This model was selected because mice develop a chronic colitis that resembles Crohn's disease. il10 Ϫ/Ϫ mice (5Ϫ6 weeks) were fed piroxicam in nonfluorescent food for 2 weeks (week 1: 180 mg · kg Ϫ1 food; week 2: 260 mg · kg Ϫ1 food), followed by piroxicam-free food for 8Ϫ10 days before study. Control mice were age-and sex-matched wild-type mice that did not receive piroxicam.
Trinitrobenzene sulfonic acid؊induced colitis in C57/BL6, cat-s ؉/؉ and cat-s ؊/؊ mice. This model was selected because trinitrobenzene sulfonic acid (TNBS)-induced colitis is associated with colonic hyperalgesia, and the model allows convenient study of genetically modified mice. Mice were fasted overnight and sedated with isoflurane. TNBS (2 mg/ mouse, 50% ethanol/saline, 50 L) or vehicle (control) was injected via a PE10 catheter inserted 4 cm from the rectum. Mice were studied after 3 days.
Administration of activity-based probes. GB123 (250 M, 66% dimethyl sulfoxide/phosphate-buffered saline, 100 L, intravenous) was administered 24 h before study. GB137 (31 M, 8% dimethyl sulfoxide/phosphate-buffered saline, 10 L) was injected intrathecally and 3 h later spinal cord (T13ϪL5) was collected for analysis. To identify proteases in the colonic lumen, mice were anesthetized with isoflurane and a 2 cm length of proximal colon was ligated to form a closed loop. GB123 (1 M, 20 mM sodium acetate [pH 7.4], 5 mM EDTA, 5 mM dithiothreitol [DTT] , 250 L) was injected into the loop and 5 min later the loop fluid was collected and centrifuged (16,100g, 5 min, 4°C) . Samples (100 g protein) were analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and in-gel fluorescence.
Noninvasive imaging. Sequential fluorescence tomographic (FT), magnetic resonance, and x-ray computerized tomography images were acquired from mice immediately after death. The same FT imaging parameters were used for all mice, and the images are shown with the same fluorescence gating and are quantified as the relative increase in signal above baseline. GB123 signals were quantified in the excised colon by reflectance imaging.
Immunofluorescence and cellular confocal imaging. Tissues were fixed in 4% paraformaldehyde, 0.1 M phosphate-buffered saline (pH 7.4) (2 h, room temperature). Frozen sections were processed for indirect immunofluorescence, and were observed by laser scanning confocal microscopy. Identical parameters were used to acquire images of control and inflamed tissues.
SDS-PAGE, Western blotting, and immunoprecipitation. Tissue homogenates (35Ϫ50 g) were analyzed by SDS-PAGE (15%), and ABP-bound proteins were detected by in-gel fluorescence. Signals were normalized to ␤-actin, detected by Western blotting. For immunoprecipitation, homogenates (100 g protein) were incubated with Cat-B, Cat-L, or Cat-S antibodies, followed by protein A/G beads. Immunoprecipitates were analyzed by SDS-PAGE and in-gel fluorescence.
In vitro reactions with ABPs. Homogenates (100 g protein) were incubated with GB123 or GB138 Cat-S-induced colonic inflammation and pain. Human Cat-S (5 g, 50 L) or vehicle (0.9% saline) was injected via a catheter inserted 3 cm from the rectum. Some mice were pretreated with the irreversible Cat-S inhibitor morpholinurealeucine-homophenylalanine-vinyl phenyl sulfone 3 (250 nM, 50 L intracolonic injection) 30 min before Cat-S. At 15 min after Cat-S, ethanol (35%, 50 L) was similarly administered to promote mucosal permeability. At 1 h after Cat-S, visceromotor responses (VMR) were recorded by electromyography of abdominal muscles. 15, 16 Colorectal distension (CRD) was induced by distension of a colonic balloon (15Ϫ60 mm Hg). To assess activation of nociceptive neurons in the spinal cord, c-fos was localized in the spinal cord collected 2 h postϪCat-S. 15 To assess inflammation, myeloperoxidase activity was measured in colonic extracts at 1.5 h post-Cat-S. 17 Electrophysiological recordings from colonic dorsal root ganglia neurons. Dorsal root ganglia (DRG) neurons innervating the colon of C57BL/6 mice were identified by retrograde tracing. 18 DRG (T9ϪT13) were dissociated and cultured overnight. 18 Patch clamp recordings were made in current clamp mode at room temperature from small neurons with a capacitance of Յ40 pF (putative nociceptive neurons). Intrinsic excitability was assessed using 500-ms duration current injections to establish the rheobase (firing threshold) and the number of action potentials at twice the rheobase during the 500-ms pulse. Neurons were exposed to human Cat-S (500 nM) or vehicle (control) for 60 min prior to patch clamping.
Statistical Analysis
Data are mean Ϯ standard error of mean from 4Ϫ6 mice per group. Differences were examined using analysis of variance and Dunnett's post-hoc test or using Student's t test. P Ͻ .05 was considered significant.
Results

Noninvasive Optical Imaging of Activated Cathepsins in the Inflamed Intestine
To localize activated cathepsins in the intestine, we administered GB123 to control and piroxicam-treated il10 Ϫ/Ϫ mice. GB123 was detected by FT imaging after 24 h, when excess unbound probe was excreted, and sequential magnetic resonance and computerized tomography images were obtained to define the location of GB123 signals. In control mice without colitis, GB123 fluorescence in the abdomen was minimal after 24 h, consistent with excretion of unbound probe ( Figure 1A) . In piroxicam-treated il10 Ϫ/Ϫ mice, with histologically documented inflammation of colon and cecum (not shown), GB123 signals were detected throughout the intestine, indicated by coronal, transverse and lateral FT images of the abdomen ( Figure 1A ). Total abdominal GB123 fluorescence was 32-fold increased in piroxicam-treated il10 Ϫ/Ϫ mice compared to control mice ( Figure 1B) . Analysis of coregistered FT, magnetic resonance, and computerized tomography images of the abdomen in the coronal and transverse plane revealed a low GB123 signal in the large intestine of control mice that was markedly increased in mice with colitis, although GB123 fluorescence was also increased in other regions of the bowel and the liver ( Figure 1C ). GB123 accumulation in the inflamed colon was confirmed by reflectance imaging of excised colon ( Figure 1D ).
Cellular Confocal Imaging of Activated Cathepsins in the Inflamed Intestine
To confirm activation and to identify the cellular source of cathepsins, we localized GB123-bound proteases in the colon by confocal microscopy. In control animals, there was minimal detectable GB123 fluorescence in sections of colon collected 24 h after administration of GB123 (Figure 2A ), consistent with results from FT. In contrast, GB123 was detected in multiple discrete cells in the lamina propria and submucosa of the colon of piroxicam-treated il10 Ϫ/Ϫ mice ( Figure 2A ). Most GB123-stained cells expressed F4/80-immunoreactive (IR), which identifies macrophages that were markedly up-regulated in the inflamed colon (Figure 2A , arrows). GB123 was also detected in macrophages in the mucosal vasculature, consistent with infiltration of macrophages into the inflamed colon ( Figure 2A , arrow heads). High-magnification images indicated that GB123 was localized to discrete vesicles of macrophages, which probably represent lysosomes or endosomes ( Figure 2A= ). Because GB123 covalently binds Cat-B, Cat-L, and Cat-S, 11, 12 we simultaneously localized 
Proteomic Identification of Activated Cathepsins in the Inflamed Intestine
Because ABPs covalently modify activated proteases, probe-bound proteases can be fractionated by gel electrophoresis and identified immunochemically. 11, 12 To characterize activated cathepsins in the inflamed intestine, we fractionated intestine from mice treated with GB123 by SDS-PAGE and detected probe-bound proteases by in-gel fluorescence. GB123-bound proteases were detected in extracts of proximal colon and cecum of piroxicam-treated il10 Ϫ/Ϫ mice corresponding in size to Cat-B (31 kDa), Cat-S (28 kDa), and Cat-L (25 kDa) (Figure 3Ai and Bi). When compared to control mice, signals in the proximal colon of piroxicam-treated il10 Ϫ/Ϫ mice were up-regulated by 2.0-fold for Cat-B, 1.7-fold for Cat-L, and 1.7-fold for Cat-S (all P Ͻ .05 to control) (Figure 3Ai ). In the cecum, signals were increased by 3.0-fold for Cat-B, 2.2-fold for Cat-L, and 3.0-fold for Cat-S (Cat-S, Cat-L; P Ͻ .05 to control) (Figure 3Bi ). To confirm the identity of GB123-bound proteases, Cat-B, Cat-L, and Cat-S were immunoprecipitated from extracts of inflamed proximal colon and cecum, and immunoprecipitates were analyzed by in-gel fluorescence. This analysis identified Cat-B, Cat-L, and Cat-S in the proximal colon and cecum of piroxicam-treated il10 Ϫ/Ϫ mice (Figure 3C ). Western blotting of purified proteases confirmed that antibodies were selective for Cat-B, Cat-L, and Cat-S (not shown). GB123 also labeled purified proteases (Figure 3D ). To determine whether these proteases are secreted into the intestinal lumen, we injected GB123 into a closed loop of proximal colon from control and piroxicam-treated il10 Ϫ/Ϫ mice, and after 5 min analyzed luminal fluid by SDS-PAGE and in-gel fluorescence. GB123-bound proteases corresponding to Cat-B and Cat-S were detected in the lumen of control and inflamed colon (Figure 3Ei ). However, Cat-S alone was activated by 4.7-fold in lumen of the inflamed colon. These results confirm activation of Cat-B, Cat-L, and Cat-S in colitis, and reveal secretion of activated Cat-S. 
Intracolonic Cat-S Causes Visceral Hyperalgesia and Activates Spinal Nociceptors via PAR 2
Subsequent studies focused on Cat-S, which was robustly activated in the inflamed intestine and selectively secreted into the colonic lumen, and which remains active at extracellular pH. To determine whether Cat-S causes visceral pain, we administered Cat-S (5 g) or vehicle into the colonic lumen of C57/BL6 mice. Pain was assessed by determining VMR to graded CRD, and activation of spinal nociceptive neurons was evaluated by quantifying cfos-IR in nuclei within laminae I/II of the spinal cord. Within 1 h of administration, Cat-S significantly increased the VMR to all CRD pressures (15, 30, 45 , 60 mm Hg) compared to vehicle or to basal measures ( Figure 4A ). The greatest difference between vehicle (0.14 Ϯ 0.03 mV · s) and Cat-S (0.34 Ϯ 0.08 mV · s) (2.4-fold; P Ͻ .05) was observed at 30 mm Hg. Pretreatment with the Cat-SϪse-lective inhibitor morpholinurealeucine-homophenylalanine-vinyl phenyl sulfone abolished the pronociceptive actions of Cat-S, indicating a requirement for protease activity ( Figure 4A ). Cat-S can activate PAR 2 , 5 an established mediator of visceral hyperalgesia, 7 but the role of PAR 2 in Cat-SϪmediated pain has not been examined. To determine whether PAR 2 mediates Cat-SϪinduced visceral pain, we administered Cat-S into the colonic lumen of par 2 ϩ/ϩ and par 2 Ϫ/Ϫ mice. In par 2 ϩ/ϩ mice, Cat-S amplified the VMR to CRD in a similar manner to C57/BL6 mice ( Figure 4B ). Cat-S also increased the number of c-fos-IR nuclei by 2.2-fold over vehicle (vehicle, 9.1 Ϯ 0.8; Cat-S, 20.3 Ϯ 2.3; P Ͻ .05) in laminae I/II of the dorsal horn ( Figure 4C and C=) . However, Cat-S neither increased the VMR to CRD ( Figure 4B ) nor increased the number of c-fos-IR nuclei in the dorsal horn ( Figure Ci and Cii) of par 2 Ϫ/Ϫ mice. Moreover, Cat-S did not affect myeloperoxidase activity in the colon of par 2 ϩ/ϩ mice ( Figure 4D ). Thus, luminal Cat-S amplifies VMR to CRD and activates spinal nociceptive neurons by a PAR 2 -dependent mechanism.
Cat-S Induces Hyperexcitability of Colonic Nociceptors
To determine whether Cat-S can directly excite colonic nociceptors, we examined the effects of Cat-S on membrane currents of DRG neurons innervating the colon. Using whole cell perforated patch techniques, the rheobase and action potential discharge at 2 times rheo- base were measured. Cat-S (500 nM, 60 min) decreased (24%, P Ͻ .05) rheobase and increased (116%, P ϭ .006) action potential firing at twice rheobase in colonic DRG neurons of C57/BL6 mice ( Figure 5A ). Cat-S treated with the cysteine cathepsin inhibitor E64 (100 M) had no effect on membrane currents, indicating a requirement for proteolytic activity ( Figure 5B ). DRG neurons from par 2 Ϫ/Ϫ mice did not respond to Cat-S, suggesting that PAR 2 mediates Cat-SϪinduced neuronal hyperexcitability ( Figure 5C ).
Cat-S Has a Causative Role in Colonic Inflammatory Pain
Inflammation of the colon and agonists of PAR 2 induce hyperalgesia to colorectal distension. 7, 15, 16 To selectively determine the contribution of Cat-S to colonic hyperalgesia, we examined the VMR to CRD in cat-s ϩ/ϩ and cat-s Ϫ/Ϫ mice with TNBS-induced colitis. This genetic approach obviated to use protease inhibitors that can exert off-target effects, and TNBS was selected as an inflammatory stimulant that is known to cause colonic hyperalgesia. 15 Before TNBS administration, there were no differences in VMR between cat-s ϩ/ϩ and cat-s Ϫ/Ϫ mice and all CRD pressures, indicating that Cat-S is not required in colonic mechanical sensation under unstimulated conditions ( Figure 6A ). In cat-s ϩ/ϩ mice, at day 3 post-TNBS the VMR was significantly increased over baseline at CRD to 45 and 60 mm Hg ( Figure 6A ). However, in cat-s Ϫ/Ϫ mice, the VMR response post-TNBS was not significantly different from baseline to any CRD pressures. The difference in VMR was most apparent at 60 mm Hg, when the VMR response in cat-s ϩ/ϩ mice was 2.0-fold over basal and the response in cat-s Ϫ/Ϫ mice was 1.4-fold over basal. To confirm that cathepsins were also activated during TNBS colitis, we administered GB123 to mice and analyzed colonic homogenates collected 24 h later. GB123-bound proteases corresponding to Cat-S and Cat-B were detected, and Cat-S was up-regulated by 2.5-fold and Cat-B by 4.2-fold in mice with TNBS colitis compared to controls ( Figure 6B ).
Cathepsins Are Activated in the Spinal Cord During Colitis
Cat-S is activated in spinal microglial cells after nerve injury and contributes to neuropathic pain. 3, 4 It is not known whether visceral inflammation affects cathepsin activity in the spinal cord. To determine whether colitis results in activation of spinal cathepsins, we administered GB137 by intrathecal injection to mice. A quenched probe, which fluoresces only after proteolytic attack, was selected to avoid the requirement for clearance of unbound probe prior to analysis, which may be slow from spinal fluid. Confocal imaging of sections of spinal cord that receive input from colonic sensory nerves (T13ϪL2) collected 3 h after probe injection revealed a low level of GB137 fluorescence in control animals, but GB137 accumulated throughout the spinal cord of piroxicam-treated il10 Ϫ/Ϫ mice ( Figure 7A ). GB137 colocalized with Lamp1-IR in spinal neurons, identified by NeuN-IR, and was also detected in microglial cells that were iden- mice, Cat-S had no effect on rheobase or action potential firing. *P Ͻ .05, **P Ͻ .01 to vehicle, (n) ϭ number of neurons. tified by Ox42-IR. Notably, GB137 partially colocalized with Cat-S-IR in microglial cells. Analysis of extracts of spinal cord from GB137-treated mice by SDS-PAGE and in-gel fluorescence did not reveal signals that were sufficiently strong to quantify. However, Cat-B, Cat-L, and Cat-S were identified in homogenates of spinal cord that were incubated with GB138 (Figure 7Bi ). Quantification revealed that Cat-B, Cat-S, and Cat-L were up-regulated in the spinal cord of mice with colitis (Figure 7Bii ). Cat-B and Cat-S were identified by immunoprecipitation ( Figure 7C ).
Discussion
Despite the importance of proteases and PARs for inflammation and pain, the spectrum of proteases that are activated in inflammatory diseases is unclear, and their identity, cellular origin, mechanism of action, and causative roles of specific activated proteases are not defined. By administering near-infrared ABPs to mice with chronic colitis, we detected increased cysteine cathepsin activity in the colon by noninvasive imaging, and localized this activity to macrophages by confocal imaging. Proteomic analysis identified activated Cat-B, Cat-L, and Cat-S. Cat-S activity was selectively increased in the lumen during colitis, indicating secretion, and luminal Cat-S caused colonic pain and increased excitability of colonic nociceptive neurons by a PAR 2 -dependent mechanisms. Cat-S deletion attenuated inflammatory pain of the colon. Our results reveal activation of cathepsins in macrophages of the inflamed colon, and identify Cat-S as a new mediator of colonic pain. ABPs offer a powerful approach to detect and identify the spectrum of proteases that are activated during disease, and may represent a diagnostic approach that identifies causative biomarkers of disease.
Inflammation-Induced Activation of Cathepsins in the Colon and Spinal Cord
Our results show that Cat-S is activated in macrophages and that Cat-B and Cat-L are activated in macro- phages and colonocytes in the colon of piroxicam-treated il10-ko mice, which develop colitis that resembles Crohn's disease. Noninvasive FT imaging detected accumulation of GB123 in the colon of mice with colitis, and confocal imaging showed that GB123 mainly accumulates in infiltrating macrophages of the lamina propria, although GB123 was also detected in epithelial cells. Although it is not possible to unequivocally determine which activated cathepsins bind to GB123 in these cells, Cat-S-IR was confined to macrophages, and Cat-B-IR and Cat-L-IR were detected in macrophages and colonocytes. Analysis of colonic extracts by electrophoresis revealed that GB123 was bound to proteases corresponding in mass to Cat-B, Cat-L, and Cat-S, which were identified by immunoprecipitation. Our results confirm a major role for macrophages and cathepsins in intestinal inflammation. 19 Cat-B, Cat-D, and Cat-L are up-regulated in macrophages in the colon of patients with inflammatory bowel disease and mice with colitis, 20, 21 Cat-K is expressed by granulomas of patients with Crohn's disease, 22 and Cat-G is up-regulated in biopsies from patients with ulcerative colitis. 23 Although these studies observed up-regulation of cathepsin mRNA and protein during colitis, they did not assess enzymatic activity, the key determinant of protease function. Activity assays usually rely on use of substrates and inhibitors that lack absolute specificity, and are unsuitable for localization of activated proteases by noninvasive or cellular imaging. By using near-infrared APBs that covalently label only active proteases, we were able to localize activity and identify activated Cat-B, Cat-L, and Cat-S. Of these, Cat-S was selectively activated in the lumen during colitis, suggesting secretion from macrophages. Although other cathepsins may also be secreted, Cat-S is unusual in that it retains full activity at normal extracellular pH. Cat-B is also released from intestinal segments after injury, 24 and activity of Cat-G, a neutrophil serine protease, is also increased in feces of ulcerative colitis patients. 23 A drawback of unquenched probes such as GB123 is that they fluoresce whether or not they are bound to proteases, necessitating imaging 24 h after systemic administration, when unbound probe is cleared. 11, 12 To determine whether cysteine cathepsins are also activated in the spinal cord during colitis, we intrathecally administered GB137, a quenched ABP that fluoresces only after protease attack. This approach enabled localization of proteases in tissues where clearance of unbound probe could be delayed. Colitis induced accumulation of GB137, indicative of cysteine cathepsin activation, in neurons and microglial cells throughout the spinal cord. To our knowledge, the activation of spinal cathepsins during colitis has not been reported previously. Peripheral nerve injury results in up-regulation, activation, and release of Cat-S from spinal microglial cells. 3, 4 Given the extensive activation colonic sensory nerves during colitis, 25 it is likely that activated Cat-S contributes to the GB137 signal, particularly in microglial cells. Indeed, GB137 accumulated in Cat-S expressing microglial cells.
Causative Role of Cysteine Cathepsins in Colonic Inflammation and Pain
The administration of Cat-S into the colonic lumen, to mimic the increased activity observed during colitis, enhanced the nocifensive response of mice to colorectal distension, suggesting mechanical hyperalgesia, and induced c-fos expression in neurons in superficial laminae of the spinal cord, consistent with activation of spinal nociceptive neurons. These changes occurred without obvious signs of inflammation, assessed by measurement of granulocyte infiltration. Cat-S deletion did not affect the response to colonic distension under basal conditions, suggesting that Cat-S does not contribute to mechanotransduction in the colon. However, in mice with TNBS colitis, Cat-S deletion decreased the VMR to 60 mm Hg distending pressure by 32%, implicating Cat-S as a mediator of inflammatory hyperalgesia in the colon. Given the robust activation of colonic Cat-S during colitis, it is likely that Cat-S causes pain by peripheral mechanisms, and further work is required to examine the role of spinal Cat-S in visceral pain. Inhibitors of Cat-B, Cat-L, and Cat-D also ameliorate colitis in mice, 21 although the role of these proteases in visceral pain has not been examined.
Mechanisms of Cathepsin-Induced Inflammation and Pain in the Colon
In addition to their physiological roles in intracellular antigen presentation, zymogen activation and hormone processing, secreted cysteine cathepsins contribute to inflammatory diseases of multiple systems. 1,2 During chronic inflammation, macrophages destroy extracellular matrix by secreting Cat-B, Cat-L, and Cat-S, 26 which may aggravate colitis by promoting paracellular permeability and influx of inflammatory cells. Inflammatory mediators stimulate Cat-S secretion from macrophages and microglial cells, 27 and secreted Cat-S is active at normal extracellular pH and may have widespread extracellular actions. 2 Because Cat-S derives from macrophages and spinal microglial cells, peripheral and central neuroimmune mechanisms could mediate its effects on inflammation and pain (Supplementary Figure 1) . We observed that par 2 deletion attenuated the effects of intracolonic Cat-S on visceromotor responses and c-fos expression in spinal neurons, and abolished Cat-SϪinduced hyperexcitability of nociceptive neurons. These result is consistent with the report that Cat-S can activate heterologously expressed PAR 2 . 5 Activation of PAR 2 on primary spinal afferent neurons innervating the colon induces neurogenic inflammation and pain, [7] [8] [9] 25 and PAR 2 activation on colonocytes increases paracellular permeability. 6, 28 Thus, Cat-S may induce colonic pain and inflammation by activating PAR 2 on several cell types. Although our results show that expression of PAR 2 is necessary for Cat-SϪinduced hyper-algesia, we did not directly examine whether Cat-S cleaves PAR 2 , and thus cannot exclude the possibility that Cat-S activates other proteases that in turn activate PAR 2 . Furthermore, Cat-S released from spinal microglial cells during nerve injury liberates fractalkine from dorsal horn neurons, thereby contributing to the amplification and maintenance of chronic pain, 3, 4 and similar mechanisms may occur during colitis (Supplementary Figure 1) .
Conclusions
We conclude that Cat-B, Cat-L, and Cat-S are activated in macrophages during colitis, and that secreted Cat-S causes colonic pain and hyperexcitability of colonic nociceptive neurons via PAR 2 . Cysteine cathepsin inhibitors may be used to treat colonic pain and inflammation. ABPs enable identification of activated proteases during colitis. Given the recent advances in fluorescence endoscopy, 29 near-infrared ABPs and imaging may facilitate early diagnosis and provide mechanistic insights into colonic disease.
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RIPA buffer, and analyzed by SDS-PAGE and in-gel fluorescence.
Cat-S؊Induced Colonic Inflammation and Pain
Mice were sedated with isoflurane. Human Cat-S (5 g, 50 L) or vehicle (0.9% saline) was injected via a PE10 catheter inserted 3 cm from the rectum. Mice were held inverted to prevent leakage. One group of mice were treated with the irreversible Cat-S inhibitor morpholinurea-leucine-homophenylalanine-vinyl phenyl sulfone (LHVS) 3 (250 nM, 1% dimethyl sulfoxide, 10% Tween80, 89% saline, 50 L intracolonic injection), 30 min before Cat-S. After 15 min after Cat-S administration, ethanol (35%, 50 L) was similarly administered to promote mucosal permeability. At 1 h after Cat-S administration, VMR were recorded by electromyography of abdominal muscles. 4, 5 CRD was induced by graded distensions of a colonic balloon using helium (15, 30, 45 , 60 mm Hg, three 10-s trials at each pressure, 2 min recovery between each distention). Electromyography records were quantified by integrating rectified signals obtained during the stimulus and are expressed as mV · s. To assess activation of nociceptive neurons in the spinal cord, c-fos was localized in the spinal cord collected 2 h after Cat-S administration. 4 c-Fos-IR nuclei in laminae I and II of the dorsal horn (T12ϪL2) were counted in 5 sections per segment per mouse using a computer-assisted image analysis system (NIH Image). To assess inflammation, myeloperoxidase activity was measured by enzymatic assay of colon collected 1.5 h after Cat-S administration. 6 Data are expressed as mU myeloperoxidase · mg Ϫ1 colonic tissue. (7) Cat-S can also cleave membrane-tethered fractalkine (FKN) on spinal neurons. Soluble FKN can activate CX3CR1, which is expressed by microglial cells, to induce the release of inflammatory mediators such as interleukin (IL)-1␤ and IL-6. These cytokines are known to cause pain. This hypothesis is based on other studies of protease-and PAR 2 -induced neurogenic inflammation and pain, and on studies examining the contribution of microglial-derived Cat-S to neuropathic pain. Further studies are required to determine the contribution of these mechanisms to inflammatory pain of the colon. See text for references.
Electrophysiological Recordings From Colonic DRG Neurons
DRG neurons innervating the colon in C57BL/6 mice were identified by retrograde tracing injecting the fluorescent retrograde tracer Fast Blue (Cedarlane Laboratories; Homby, ON, Canada) into the wall of the colon, as described. 7 To isolate DRG neurons for patch clamp studies, mice were anesthetized with ketamine and xylazine, sacrificed by transcardial perfusion, and DRG (T9ϪT13) were dissociated. 7 Dispersed neurons were suspended in Dulbecco's modified Eagle medium (pH 7.2Ϫ7.3) containing 10% fetal bovine serum, 100 U/mL penicillin, 0.1 mg/mL streptomycin, and 2 mM glutamine, plated on poly-D-lysine/laminin-coated cover slips and incubated overnight in a humidified incubator (95% O 2 , 5% CO 2 , 37°C). Amphotericin-perforated patch clamp experiments were performed in current clamp mode at room temperature. Recordings were made from small neurons with a capacitance of Յ40 pF, which are putative nociceptive neurons. Signals were acquired using an Axopatch 200B amplifier and digitized with a Digidata 1322A A/D converter (Axon Instruments, Sunnyvale, CA). Signals were low-pass filtered at 5 kHz, acquired at 20 kHz, stored and analyzed using Clampfit 9 (Axon Instruments). Inclusion criteria included resting membrane potential more negative than Ϫ45 mV and overshooting action potentials with a hump on the falling phase. Solutions (mM) were the extracellular solution: 140 NaCl, 5 KCl,1 MgCl 2 , 2 CaCl 2 , 10 HEPES, 10 D-glucose (pH 7.4) and pipette solution: 110 potassium gluconate, 30 KCl, 10 HEPES, 1 MgCl 2 , 2 CaCl 2 (pH 7.25). The liquid junction potential was taken to be 12 mV, which was used for correction. Intrinsic excitability of neurons was assessed using 500-ms duration current injections to establish the rheobase (firing threshold) and the number of action potentials at twice the rheobase during the 500-ms pulse. Neurons were exposed to human Cat-S (500 nM) or vehicle (control) for 60 min prior to patch clamping.
